Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention

Table 2

Angiographic procedural characteristics of the study population, mean ± SD or n (%).

Variable	Control group (n = 192)	CSF/NRF group (n = 50)
Preoperative SBP (mmHg)	131.5 (118.0, 145.8)	116.0 (106.8, 132.0)	≤0.001
Preoperative DBP (mmHg)	79.0 (70.0, 89.0)	72.5 (65.0, 84.3)	≤0.001
Intraoperative hypotension	57 (29.7)	29 (58.0)	≤0.001
Position of myocardial infarction	—	—	0.095
Anterior wall	90 (46.9)	19 (39.5)	—
Lateral wall	18 (9.4)	2 (2.3)	—
Inferior wall	83 (43.2)	29 (60.5)	—
Posterior wall	8 (4.2)	6 (14.0)	—
Right ventricle	18 (9.3)	7 (16.3)	—
Infracted arteries (n, %)	—	—	0.119
LAD	85 (50.0)	15 (34.9)	—
LCX	11 (6.5)	1 (2.3)	—
RCA	74 (43.5)	27 (62.8)	—
LM involvement	24 (12.5)	3 (6.0)	0.193
Diffuse lesions (n, %)	67 (34.9)	16 (32.0)	0.701
Gensini lesions (n, %)	63.5 (43.0,88.0)	62.0 (44.5,92.8)	0.806
Stent length (mm)	29.0 (19.0, 43.0)	39.5 (28.0, 51.0)	0.118
Contrast agent dosage (ml)	130 (110, 160)	135 (127, 160)	0.468

Bold values are statistically significant().